SCCR 34 Limitations and Exceptions for libraries and archives
May 3, 2017 AM Session
SCCR 34 Limitations and Exceptions for libraries and archives
Some statements from member states regarding L&E for libraries and archives:
[…]
Search Results for: car t
SCCR 34 Update on Progress of Broadcasting, Cablecasting and Webcasting Treaty Progress (or lack thereof?)
5:55pm Plenary May 2, 2017 We were told there will be no time for NGOs to make statements.
The Chair started the Plenary at 5:55 pm or 5 minutes before the meeting was to clse for the day.
In brief:
- No recommendation to the GA for a Diplomatic Conference in 2018 (not ready for prime time).
- The Chair’s text is being replaced by a “committee Text”.
- The EU is not happy.
- The broadcasting treaty has stalled. Again.
Here is the transcript of what we can share:
Detailed Presentation of New Casting Text to be discussed at SCCR34
CAROLE CROELLA, WIPO Secretariat:
Thank you Mr. Chair and good morning, everyone. I will indeed try to take the committee into the main changes and highlights of this new text. I’m not sure it will be a swinging presentation, Mr. Chair, but I will try to do my best.
SCCR34 Statements regarding the Broadcasting Treaty
EUROPEAN UNION:
The treaty on broadcasting organizations is a high priority for the European Union and its Member States. We are strongly committed to advancing work on the various work of the previous sessions. We look forward to discussing the issues set out wherein.
We hope that further progress can be made on the basis of the revised consolidated text, on the rights to be granted and other issues that has been prepared nor this session.
We hope that further progress can be made on the basis of the revised consolidated text, on the rights to be granted and other issues that has been prepared nor this session.
General Statements by Regional Groups regarding the Agenda of SCCR 34
GRULAC:
COLOMBIA: Thank you, Mr. Chairman. The delegation of Colombia has the honor of making this declaration on behalf of the group of Latin America and Caribbean countries. We congratulate you on the chairmanship of this important committee and we congratulate your new vice chairs.
We remember the important work of the previous chair and vice chairs. We would like to thank the Secretariat for preparation and organization of this session and also for publication of the documents for our consideration.
WIPO SCCR 34 May 1, 2017 Day 1: Agenda and Election of New Chair and Vice Chairs
The DG, Franci Gurry, started the SCCR meeting with a summary of the issues to be discussed, some old (Broadcasting treaty, Limitations and Exceptions for libraries, archives, museum and education and for people with other disabilities) some new or “exploratory” (GRULAC proposal on copyright and digital works and resale rights):
DIRECTOR GENERAL: […]
Continue Reading
How Sanofi Prices Its MS Drug Aubagio (Teriflunomide) in the U.S. and Five Reference Countries
The U.S. Army recently rejected requests by public interest groups, Senator Bernie Sanders, and almost a dozen House Democrats to refuse to grant Sanofi an exclusive license on patents on a Zika virus vaccine, or, alternatively, to ensure that the license included terms assuring that U.S. taxpayers would not pay a higher price than other high-income countries. Specifically, KEI proposed the following terms to be included in the contract:
Sanofi fines for fraud, kickbacks, etc
April 3, 2017. Sanofi agreed to pay $19.9 million to resolve allegations under the False Claims Act that the company overcharged the U.S. Department of Veterans Affairs (VA) for drugs under two contracts between 2002 and 2011. According to the DOJ press release:
KEI Statement on House Letter to President Trump on the Protection of Taxpayers’ Rights in Federally-Funded Inventions
4 APRIL 2017
FOR IMMEDIATE RELEASE
CONTACT: Zack Struver, zack.struver@keionline.org or +1 (202) 332-2670
In a letter sent today, Representative Lloyd Doggett, D-Texas, and 50 other democratic members of Congress requested that President Donald J. Trump issue guidance for the use of Bayh-Dole Act march-in rights in order to protect taxpayer’s rights in federally-funded patented inventions.
The following statement should be attributed to James Love, Director of Knowledge Ecology International (KEI):
“The letter from members of Congress on the need to protect taxpayer’s rights in the inventions they fund is important, timely, and directly related to the challenge of providing affordable health care to everyone. Federally-funded inventions are now routinely placed on the market at extremely high prices. Astellas charges more than $350 per day for the prostate cancer drug Xtandi, and BioGen is charging $1.125 million for the first two years of Spinraza, which is used to treat spinal muscular atrophy in mostly young children. The notion that the federal government will not engage on the pricing of these products runs counter to the explicit provisions in the Bayh-Dole Act that require inventions be made ‘available to the public on reasonable terms.’ The President can curb high prices for these drugs without new legislation, and without putting patients at risk.”
KEI filed the most recent march-in request with the federal government on the prostate cancer drug Xtandi.
The letter is available as a PDF here and below in plain text.
Representative Doggett’s office issued the following press release: https://doggett.house.gov/media-center/press-releases/congressional-democrats-trump-we-re-calling-your-hand-lower-prescription
KEI statement: 21st meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines
On Monday, 27 March 2017, Knowledge Ecology International (KEI) delivered the following oral statement to the Open Session of the 21st Meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines. The program for the open session can be found here.